An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

Abstract Human epidermal growth factor receptor 2 (HER2) is overexpressed in breast and gastric cancers and this causes poor clinical outcomes. Although both T‐DM1 and Enhertu are approved as an HER2‐targeting antibody‐drug conjugate (ADC), the effects of these drugs are still not satisfactory to er...

Полное описание

Библиографические подробности

Главные авторы:	Seol Hwa Shin, Yun‐Hee Park, Seok Soon Park, Eun Jin Ju, Jin Park, Eun Jung Ko, Dong Jun Bae, Sang‐Yeob Kim, Chul‐Woong Chung, Ho Young Song, Se Jin Jang, Seong‐Yun Jeong, Si Yeol Song, Eun Kyung Choi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2021-12-01
Серии:	Advanced Science
Предметы:	antibody drug conjugate HER2 patient derived xenograft (PDX)
Online-ссылка:	https://doi.org/10.1002/advs.202102414
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!